by Blood Advances
Toxicities related to axicabtagene ciloleucel (axi-cel) can be safely and effectively managed, suggest findings from a single-center study.
by Clinical Cancer Research
While evidence suggests that increasing the share of stem cell-like memory T cells (TSCM) in chimeric antigen receptor (CAR) T-cell products might support immunotherapy for solid tumors, a Phase I...
by Blood Advances
Donor T cells that overexpress the protein BCL2, including those enriched after steroid exposure, protect against graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell...
by Clinical Cancer Research
Researchers have demonstrated the potential for selective irreversible electroporation (sIRE) to improve chimeric antigen receptor (CAR) T-cell function in solid tumors, thus lowering cancer...
by Cell Transplantation
Scientists have developed an advanced therapy medicinal product (ATMP) that aims to protect leukemia patients against tumor relapse and potentially fatal infection following haploidentical...
by Translational Oncology
Researchers believe development of chimeric antigen receptor (CAR) T cells targeting the C-X-C chemokine receptor type 4 (CXCR4) could play a role in treating both acute myeloid leukemia (AML) and...